Trial Condition(s):
Venous Thromboembolism
Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients with Cancer-Associated Thromboembolism Treated with Rivaroxaban
Bayer Identifier:
19622
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
To estimate the real-world rates of recurrent Venous thromboembolism (VTE), major bleeding and all-cause mortality in patients with Cancer-associated thrombosis (CAT) treated with rivaroxaban
Inclusion Criteria
- Adult patients (≥18 years-of-age) with active cancer - Patient with at least one index venous thromboembolism (VTE ) - ≥6-months of continuous eligibility prior to the index VTE event (baseline period). - Newly initiated on rivaroxaban
Exclusion Criteria
- Patients with any medical claim for Deep vein thrombosis (DVT) or Pulmonary embolism (PE) during the 6 months pre-index date - Patients with prescription claim for anticoagulation therapy during the 6-month pre-index VTE period
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | Status | |
|---|---|---|
Locations US database New York, United States, 10001 | Status Completed | Contact Us: E-mail: [email protected] Phone: +49 30 300139003 |
Trial Design
Characterizing Recurrent Thromboembolism, Major Bleeding and All-Cause Death in Patients with Cancer-Associated Thromboembolism Treated with Rivaroxaban
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Recurrent Venous thromboembolismDerived using inpatient and outpatient medical claimsTimeframe: Retrospective analysis from November 2012 through September 2015
- Bleeding (based on the Cunningham algorithm)Derived using inpatient and outpatient medical claimsTimeframe: Retrospective analysis from November 2012 through September 2015
- Mortality (In-hospital mortality or need for hospice care without subsequent healthcare claims)Derived using inpatient and outpatient medical claimsTimeframe: Retrospective analysis from November 2012 through September 2015
Additional Information
Copyright © Bayer
Powered by
